Research programme: TRAIL receptor-based diagnostics - HGS
Alternative Names: TRAIL receptor-based diagnostics research programme - HGSLatest Information Update: 12 Apr 2017
Price :
$50 *
At a glance
- Originator Human Genome Sciences
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2010 diaDexus has been acquired by VaxGen
- 26 Apr 2007 TRAIL receptor-based diagnostics are still in active development
- 21 Oct 2003 Preclinical trials in Diagnostic tests in USA (unspecified route)